Comparison of Two Different Doses of Ampicillin-Sulbactam as Part of Combination Therapy in the Treatment of Multidrug Resistant Acinetobacter baumannii Ventilator Associated Pneumonia: A Randomized Clinical Trial

Among patients receiving combination therapy for MDR <i>Acinetobacter baumannii</i> associated VAP, higher-dose ampicillin-sulbactam was associated with improved clinical outcomes without increased toxicity. However, the small sample size, short follow-up period, and use of concomitant antibiotics limit attribution of outcomes solely to ampicillin-sulbactam dosing. Larger, well-controlled studies are needed to define the optimal dosing strategy.